Self-efficacy for coping: utility of the Cancer behavior inventory (Italian) for use in palliative care.


Journal

BMC palliative care
ISSN: 1472-684X
Titre abrégé: BMC Palliat Care
Pays: England
ID NLM: 101088685

Informations de publication

Date de publication:
05 Apr 2019
Historique:
received: 09 05 2018
accepted: 27 03 2019
entrez: 7 4 2019
pubmed: 7 4 2019
medline: 26 9 2019
Statut: epublish

Résumé

Newer models of palliative and supportive cancer care view the person as an active agent in managing physical and psychosocial challenges. Therefore, personal efficacy is an integral part of this model. Due to the lack of instruments in Italian to assess coping self-efficacy, the present study included the translation and validation of the Italian version of the Cancer Behavior Inventory-Brief (CBI-B/I) and an initial analysis of the utility of self-efficacy for coping in an Italian sample of palliative care patients. 216 advanced cancer patients who attended palliative care clinics were enrolled. The CBI-B/I was administered along with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), the Mini Mental Adjustment to Cancer Scale (Mini-MAC), the Cancer Concerns Checklist (CCL), and the Hospital Anxiety and Depression Scale (HADS). The Eastern Cooperative Oncology Group Performance Status (ECOG-PS) ratings of functional capacity were completed by physicians. Factor analysis confirmed that the structure of the CBI-B/I was consistent with the English version. Internal consistency reliability and significant correlations with the EORTC QLQ-C30, Mini-MAC, and HADS supported the concurrent validity of the CBI-B/I. Differences in CBI-B/I scores for high versus low levels of the CCL and ECOG-PS supported the clinical utility of the CBI-B/I. The CBI-B/I has strong psychometric properties and represents an important addition to newer model of palliative and supportive care. In order to improve clinical practice, the CBI-B/I could be useful in identifying specific self-efficacy goals for coping in structured psychosocial interventions.

Sections du résumé

BACKGROUND BACKGROUND
Newer models of palliative and supportive cancer care view the person as an active agent in managing physical and psychosocial challenges. Therefore, personal efficacy is an integral part of this model. Due to the lack of instruments in Italian to assess coping self-efficacy, the present study included the translation and validation of the Italian version of the Cancer Behavior Inventory-Brief (CBI-B/I) and an initial analysis of the utility of self-efficacy for coping in an Italian sample of palliative care patients.
METHODS METHODS
216 advanced cancer patients who attended palliative care clinics were enrolled. The CBI-B/I was administered along with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), the Mini Mental Adjustment to Cancer Scale (Mini-MAC), the Cancer Concerns Checklist (CCL), and the Hospital Anxiety and Depression Scale (HADS). The Eastern Cooperative Oncology Group Performance Status (ECOG-PS) ratings of functional capacity were completed by physicians.
RESULTS RESULTS
Factor analysis confirmed that the structure of the CBI-B/I was consistent with the English version. Internal consistency reliability and significant correlations with the EORTC QLQ-C30, Mini-MAC, and HADS supported the concurrent validity of the CBI-B/I. Differences in CBI-B/I scores for high versus low levels of the CCL and ECOG-PS supported the clinical utility of the CBI-B/I.
CONCLUSIONS CONCLUSIONS
The CBI-B/I has strong psychometric properties and represents an important addition to newer model of palliative and supportive care. In order to improve clinical practice, the CBI-B/I could be useful in identifying specific self-efficacy goals for coping in structured psychosocial interventions.

Identifiants

pubmed: 30953485
doi: 10.1186/s12904-019-0420-y
pii: 10.1186/s12904-019-0420-y
pmc: PMC6449975
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

34

Références

Psychooncology. 2001 May-Jun;10(3):206-17
pubmed: 11351373
JAMA. 2002 May 1;287(17):2253-60
pubmed: 11980525
Psychooncology. 2002 May-Jun;11(3):221-9
pubmed: 12112482
Psychooncology. 2003 Sep;12(6):547-56
pubmed: 12923795
Health Psychol. 2003 Sep;22(5):487-97
pubmed: 14570532
Behav Res Ther. 2004 Oct;42(10):1129-48
pubmed: 15350854
Psychooncology. 2005 Feb;14(2):115-24
pubmed: 15386782
Health Promot Pract. 2005 Apr;6(2):148-56
pubmed: 15855284
Psychooncology. 2006 Jan;15(1):79-89
pubmed: 15880660
Health Psychol. 2006 Sep;25(5):626-34
pubmed: 17014280
World J Urol. 2007 Mar;25(1):87-93
pubmed: 17066263
Pain. 2008 Jul 15;137(2):306-15
pubmed: 17942229
Psychooncology. 2008 Jun;17(6):592-7
pubmed: 17957732
Psychooncology. 2008 Nov;17(11):1146-51
pubmed: 18626853
Psychooncology. 2010 Feb;19(2):216-21
pubmed: 19378351
Psychooncology. 2010 Dec;19(12):1268-76
pubmed: 20151408
Psychol Health. 2009 Feb;24(2):149-60
pubmed: 20186648
Support Care Cancer. 2011 Apr;19(4):475-81
pubmed: 20401497
J Clin Oncol. 2010 Sep 1;28(25):4013-7
pubmed: 20660825
Psychooncology. 2011 Mar;20(3):302-12
pubmed: 20878830
Psychooncology. 2013 May;22(5):987-94
pubmed: 22573371
J BUON. 2012 Oct-Dec;17(4):785-90
pubmed: 23335542
Palliat Med. 2014 Mar;28(3):243-55
pubmed: 23935014
Recent Results Cancer Res. 1988;111:231-49
pubmed: 2459750
Support Care Cancer. 2015 Apr;23(4):1073-80
pubmed: 25281230
Support Care Cancer. 2016 Jan;24(1):109-117
pubmed: 25953381
Anticancer Res. 2017 Apr;37(4):1609-1615
pubmed: 28373421
Oncotarget. 2017 May 30;8(22):36800-36811
pubmed: 28404938
Cancer Treat Rev. 2017 May;56:16-27
pubmed: 28453966
Psychol Med. 1988 Feb;18(1):203-9
pubmed: 3363039
J Consult Clin Psychol. 1986 Dec;54(6):802-8
pubmed: 3794024
J Pers Soc Psychol. 1983 Aug;45(2):421-31
pubmed: 6620123
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Br J Cancer. 1993 Apr;67(4):773-5
pubmed: 8471434
Ann Oncol. 1998 May;9(5):549-57
pubmed: 9653497

Auteurs

Samantha Serpentini (S)

Istituto Oncologico Veneto IOV - IRCCS, Via Gattamelata, 64, 35128, Padova, Italy. samantha.serpentini@iov.veneto.it.

Paola Del Bianco (P)

Istituto Oncologico Veneto IOV - IRCCS, Via Gattamelata, 64, 35128, Padova, Italy.

Andrea Chirico (A)

"La Sapienza" University, Rome, Italy.

Thomas V Merluzzi (TV)

University of Notre Dame, South Bend, Indiana, USA.

Rosalba Martino (R)

Istituto Oncologico Veneto IOV - IRCCS, Via Gattamelata, 64, 35128, Padova, Italy.

Fabio Lucidi (F)

"La Sapienza" University, Rome, Italy.

Gian Luca De Salvo (GL)

Istituto Oncologico Veneto IOV - IRCCS, Via Gattamelata, 64, 35128, Padova, Italy.

Leonardo Trentin (L)

Istituto Oncologico Veneto IOV - IRCCS, Via Gattamelata, 64, 35128, Padova, Italy.

Eleonora Capovilla (E)

Istituto Oncologico Veneto IOV - IRCCS, Via Gattamelata, 64, 35128, Padova, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH